Trial designs used to study neuroprotective therapy in Parkinson's disease
Identifieur interne : 000100 ( France/Analysis ); précédent : 000099; suivant : 000101Trial designs used to study neuroprotective therapy in Parkinson's disease
Auteurs : Anthony E. Lang [Canada] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Olivier Rascol [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2013-01.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Neuroprotective Agents.
- drug therapy : Parkinson Disease.
- methods : Clinical Trials as Topic.
- Animals, Drug Evaluation, Preclinical, Humans, Research Design.
Abstract
There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society
Url:
DOI: 10.1002/mds.24997
Affiliations:
- Autriche, Canada, France, Israël
- Midi-Pyrénées, Occitanie (région administrative), Tyrol (Land)
- Innsbruck, Toulouse
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000947
- to stream Istex, to step Curation: 000947
- to stream Istex, to step Checkpoint: 000028
- to stream PubMed, to step Corpus: 000988
- to stream PubMed, to step Curation: 000988
- to stream PubMed, to step Checkpoint: 000988
- to stream Ncbi, to step Merge: 001232
- to stream Ncbi, to step Curation: 001232
- to stream Ncbi, to step Checkpoint: 001232
- to stream Main, to step Merge: 000F22
- to stream Main, to step Curation: 000F10
- to stream Main, to step Exploration: 000F10
- to stream France, to step Extraction: 000100
Links to Exploration step
ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.24997</idno><idno type="url">https://api-v5.istex.fr/document/1F8441423F9E5A20B3681C5AA731F29E6D85371F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000947</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000947</idno><idno type="wicri:Area/Istex/Curation">000947</idno><idno type="wicri:Area/Istex/Checkpoint">000028</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000028</idno><idno type="wicri:doubleKey">0885-3185:2013:Lang A:trial:designs:used</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:22927060</idno><idno type="wicri:Area/PubMed/Corpus">000988</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000988</idno><idno type="wicri:Area/PubMed/Curation">000988</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000988</idno><idno type="wicri:Area/PubMed/Checkpoint">000988</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000988</idno><idno type="wicri:Area/Ncbi/Merge">001232</idno><idno type="wicri:Area/Ncbi/Curation">001232</idno><idno type="wicri:Area/Ncbi/Checkpoint">001232</idno><idno type="wicri:Area/Main/Merge">000F22</idno><idno type="wicri:Area/Main/Curation">000F10</idno><idno type="wicri:Area/Main/Exploration">000F10</idno><idno type="wicri:Area/France/Extraction">000100</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Trial designs used to study neuroprotective therapy in Parkinson's disease</title><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Ontario, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>The Norma and Alan Aufzien Chair for Resarch of Parkinson's Disease, Sackler School of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea><wicri:noRegion>Tel Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Center and Department of Clinical Pharmacology and Neurosciences, CIC9302 INSERM and UMR825, Toulouse University Hospital, University of Toulouse‐3, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-01">2013-01</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="86">86</biblScope><biblScope unit="page" to="95">95</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1F8441423F9E5A20B3681C5AA731F29E6D85371F</idno><idno type="DOI">10.1002/mds.24997</idno><idno type="ArticleID">MDS24997</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic (methods)</term><term>Drug Evaluation, Preclinical</term><term>Humans</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Research Design</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Evaluation, Preclinical</term><term>Humans</term><term>Research Design</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Canada</li><li>France</li><li>Israël</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li><li>Toulouse</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></noRegion><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></country><country name="Israël"><noRegion><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></noRegion></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000100 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000100 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:1F8441423F9E5A20B3681C5AA731F29E6D85371F
|texte= Trial designs used to study neuroprotective therapy in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |